Measuring Muscle Thickness by Ultrasound in Acute Heart Failure Patients

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults in hospital with acute heart failure and cardiogenic shock, a state where the heart cannot pump enough blood. Muscle thickness is measured by ultrasound.

Age

Over 18 years (up to 100 years)

Sex

All

Disease stage

Ejection fraction below 40%. Cardiogenic shock shown by clinical signs (for example lactate above 2.5 mmol/L, systolic blood pressure below 90 mmHg, acute kidney or liver injury, or cardiac index below 2.1). Needs at least one pressor, inotrope, or temporary mechanical circulatory support device.

Earlier treatment

People with a past LVAD or other long-term ventricular assist device cannot join. People on long-term tube or intravenous feeding cannot join. Past heart transplant or being on a breathing tube does not stop a person from joining.

Main reasons for not taking part

• History of LVAD or other long-term ventricular assist device
• A disorder that causes muscle weakness or wasting (for example muscular dystrophy, mitochondrial disorder, active cancer, modified Rankin score of 4 or more after stroke)
• Long-term tube or intravenous nutrition support

The registry criteria, word for word

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

• Are you between 18 and 100 years old?YesNo

What the trial wants to find out

This study aims to determine, via skeletal muscle ultrasound (US), the extent, timing and relationship between skeletal muscle mass loss and outcomes after orthotropic heart transplantation (OHT) and left ventricular assist device (LVAD) implantation amongst patients with cardiogenic shock. Advanced therapies such as OHT and VADs in the heart failure (HF) population may promote skeletal muscle mass and subsequent quality of life, but there is a lack of literature assessing muscle mass changes in HF patients before and after advanced therapies using US imaging. Therefore this observational study will provide further insight into the 1) changes in lean body mass during critical illness and 2) the feasibility of using bedside US to assess lean body mass in the inpatient setting.

The group in the trial

• Study Cohort

  All enrolled participants with no randomization group allocations

  Treatment: BodyMetrix Body Composition Ultrasound